当前位置: 首页 > 期刊 > 《中国药房》 > 20181
编号:13605098
提升我国医药企业社会责任路径研究(5)
http://www.100md.com 2018年1月1日 《中国药房》 20181
     [ 9 ] 王鑫,甄橙.美国药品监管法規百年历程及对中国的启示[J].中国新药杂志,2016,25(8):849-854.

    [10] 徐东佳,赵迎欢.发达国家医药企业社会责任研究及启示[J].中国药房,2012,23(9):774-777.

    [11] U.S. department of state. Non-governmental organizations (NGOs) in the United States[EB/OL].[2017-03-31].https:// www.state.gov/j/drl/rls/fs/2017/266904.htm.

    [12] 田虹,黄汉瑛. 2016国外社会责任投资的中国借鉴[J].华东经济管理,2016,30(2):156-162.

    [13] MOON J,VOGEL D. Corporate social responsibility,government,and civil society[M/OL].[2017-03-31].http://www. reseurchgate.net/publication/289702652_Corporate_Social_Responsibility_Government_and_Cioil_Society.

    [14] MOON J. The social responsibility of business and new governance[J]. Government and Opposition,2002,37(33):385-408.

    [15] FOX T. Corporate social responsibility and development:in quest of an agenda[J]. Development,2004,47(3):29-36.

    [16] NUSSBAUM AK. Ethical corporate social responsibility (CSR) and the pharmaceutical industry:a happy couple?[J]. Journal of Medical Marketing,2009,9(1):67-76.

    (收稿日期:2017-04-05 修回日期:2017-10-16)

    (编辑:刘明伟), 百拇医药(沈茜)
上一页1 2 3 4 5